Success Story Of Aurobindo Realty & Infrastructure Private Limited

The company primarily manufactures active pharmaceutical ingredients (APIs) and generic drugs. Aurobindo Pharma became a publicly traded company in 1992, and in 1995 it offered its shares on Indian stock exchanges. In addition to having a presence in key therapeutic areas like gastroenterology, neurosciences, cardiovascular disease (CVS), antiretroviral, and antibiotics, Aurobindo Pharma is the market leader in semi-synthetic penicillin. More than 150 nations promote each of these products. It is R&D-focused, provides a range of products, and has manufacturing facilities dispersed across many different countries.

The business also made a foray into the lucrative speciality generic formulations market thanks to its low-cost production capabilities and a select group of loyal customers. Based on consolidated sales, Aurobindo Pharma is currently among the top 10 pharmaceutical companies in India.

Start-up Story of Aurobindo Pharma

The business was first established as a private limited company on December 26th, 1896. In Puducherry in 1988-1989, a single plant that produced semi-synthetic penicillin (SSP) was where the company’s growth took off. Within a few years, Aurobindo built another factory to make CMIC Chloride, a bulk medication intermediate, at Pashmylaram, close to Hyderabad. Aurobindo Pharma went public in 1992, and in 1995, its shares were issued on the Indian stock exchange.

Later, to develop its business operations outside of the UK, the company formed an agreement with the UK-based Glaxo (India). With the aim of teaching and treating HIV/AIDS patients in the country with prophylactic drugs, it introduced a special anti-viral branch called Immune in 2001.

Aurobindo strategically entered the high-end markets in the US and Europe in 2005 with generic formulations by taking part in the PEPFAR programme, which was established by the US government. Five years later, the business agreed to sell numerous solid dosage and sterile products for developing nations under licencing and supply agreements with AstraZeneca, one of the leading biopharmaceutical companies in the world.

Aurobindo began construction of an oral solid manufacturing facility in Taizhou, China, in 2019. The organisation has opened other locations in different nations in recent years.

Business Model for Aurobindo Pharma

Three segments make up Aurobindo Pharma’s business model:

  • Licencing of Generic/Branded Generic Products Contract Manufacturing
  • Aurobindo Company operates in more than 150 nations. There are eight significant formulation facilities in India, one in the US, and none in Brazil.

Aurobindo provided a variety of formulations, some of which are:

Cardiovascular (CVS) Products like Anti-Platelets, Beta Blockers, and ACE Inhibitors Anti-Bacterial like Penams, SSPS & Combinations, Quinolones Central Nervous System (CNS) Products like Anti-Alzheimer’s, Anti-Depressants

Additional goods, such as anti-viral, anti-diabetic, anti-fungal, etc.

The company run by Aurobindo has vertical integration and provides cutting-edge solutions. The expansion from discovery through development and commercialization is aided by its cost-effective drug development and substantial manufacturing assistance.

AuroZymes is yet another important Aurobindo company. It is a part of Aurobindo Pharma Ltd.’s biocatalysts division. AuroZymes developed and produced biocatalysts for use in the chemical and pharmaceutical industries. Originally developed for internal use, these biocatalysts are now available to Aurobindo clientele. Through AuroZymes, Aurobindo contributes to the creation of a variety of services to raise customer productivity as needed.

Another essential component of Aurobindo Pharma is AuroSource. It is a section of Aurobindo that specialises in custom research and production. The business provides project-based, customer-focused chemical services through AuroSource.

The subsidiary division of Aurobindo Pharma, Auro Peptides Ltd., is also included in the business operations of Aurobindo Pharma. It provides cutting-edge solutions for everything from research to development to commercialization to efficient drug production.

Activities of CSR by Aurobindo

Aurobindo sustainability charter covers a wide range of sustainable assistance in support of preventive healthcare, including providing access to safe drinking water, promoting education, combating hunger, poverty, and malnutrition, environmental sustainability, establishing old-age homes for the elderly, upholding ecological balance, conserving natural resources, and many more.

Future Plans for Aurobindo Pharma

In its annual report for 2021-2022, the business stated that it intended to expand its product offering with high-value cancer, hormone, and biosimilar medications as well as cutting-edge drug delivery techniques such as depot injections, inhalers, patches, and films. Since the generic drug market in these countries is so small, it has also focused on expanding geographically into new countries including Poland, Italy, Spain, the Czech Republic, Portugal, and France.

The pharmaceutical industry is also building an injectable plant exclusively for Europe and developing nations to strengthen its position in the hospital sector. It will start submitting innovative injectable medications in FY23, and commercialization could start as early as FY24.

Conclusion

The Indian multinational pharmaceutical manufacturing company Aurobindo Pharma is one of the largest producers of generic drugs globally. Its main office is located in Hyderabad, Telangana, India. Its sales were reported at $2.9 billion during FY22.

Related: 23 Innovative Green Business Ideas for Sustainable Start-ups

Leave a Reply